Go to the list of all blogs
Allana's Avatar
published in Blogs
Nov 21, 2026
TickeronGET DAILY SIGNALS
Kodiak Sciences (KOD): +10.8% Gain in 30 Days Builds on +144% Quarterly Advance

Kodiak Sciences (KOD): +10.8% Gain in 30 Days Builds on +144% Quarterly Advance

Key Takeaways

  • Kodiak Sciences (KOD) advanced roughly 10.8% over the last 30 days, rising from about $87.72 to $97.17 per share.
  • The move extends a far larger rally: over the trailing quarter, the stock gained approximately 144% from around $39.84.
  • The quarterly surge was driven primarily by positive Phase 3 DAYBREAK results for Zenkuda and tabirafusp-ted in wet AMD, announced in late September.
  • Recent 30-day gains were supported by third-quarter 2026 results, a UBS price-target increase to $150, and a consensus "Strong Buy" rating with an average target near $129.50.
  • Near-term catalysts include Zenkuda's planned fourth-quarter 2026 BLA submission and KSI-101 PEAK 1 topline data expected in December.
  • Kodiak remains a precommercial biotechnology company with no product revenue, so the stock stays highly sensitive to clinical and regulatory milestones.

Company Overview and Market Position

Kodiak Sciences Inc. is a precommercial, retina-focused biotechnology company headquartered in Palo Alto, California. The company develops treatments for major retinal vascular diseases using its proprietary Antibody Biopolymer Conjugate (ABC) platform, which is designed to extend how long therapies last inside the eye and reduce the frequency of injections.

Its lead candidate, Zenkuda (tarcocimab tedromer, formerly KSI-301), is an anti-VEGF therapy backed by five positive Phase 3 studies across wet age-related macular degeneration (wet AMD), diabetic retinopathy, and retinal vein occlusion. Kodiak is also advancing tabirafusp-ted (KSI-501), a bispecific IL-6/VEGF conjugate, and KSI-101, a bispecific targeting IL-6 and VEGF for macular edema secondary to inflammation (MESI). Investors follow the stock closely because the company is approaching its first potential regulatory filing and commercial launch. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Stock Price Performance: Last 30 Days vs. Quarter

Over the last 30 days, KOD rose from a closing price of $87.72 on October 21, 2026 to $97.17 on November 20, 2026, a gain of about 10.8%. The move was not linear: the stock climbed to a high near $111 in mid-November before pulling back modestly.

The quarterly picture is substantially stronger. Three months earlier, KOD closed at $39.84 on August 20, 2026. From that level to $97.17, the stock advanced roughly 144%, reflecting the market's re-rating of the company's late-stage pipeline after pivotal clinical data. The contrast between the two periods underscores that most of the stock's value creation occurred during a single catalyst-driven event in late September, with the last 30 days representing a more moderate consolidation of those gains. From what I see, this pattern highlights how clinical news can reshape valuations quickly.

Factors Behind the Last 30 Days

The last 30 days were shaped by follow-through from the September DAYBREAK readout and a series of company-specific updates. Kodiak reported third-quarter 2026 financial results on November 12, posting a net loss per share of $1.05 versus a consensus estimate of $1.01, and stating that its roughly $88.7 million in cash is expected to support operations into 2027.

Analyst activity also supported sentiment. UBS raised its price target on KOD to $150 from $120 while maintaining a Buy rating, and the broader analyst consensus stands at "Strong Buy" with an average 12-month target near $129.50. Additionally, Kodiak presented Phase 3 DAYBREAK data across its late-stage programs at the AAO 2026 annual meeting, reinforcing investor confidence in the pipeline ahead of the anticipated BLA filing. One thing that stands out here is how analyst upgrades can sustain momentum after a major catalyst.

What Powered the Quarterly Move

The dominant driver of the quarterly move was the September 28, 2026 announcement that Zenkuda and tabirafusp-ted both met their primary endpoints in the Phase 3 DAYBREAK study in wet AMD, demonstrating non-inferior vision gains versus aflibercept. In the study, 54% of Zenkuda-treated patients reached a six-month dosing interval under strict treat-to-dryness criteria, a durability profile that differentiates it from standard-of-care anti-VEGF therapies such as Regeneron's EYLEA.

The market reacted forcefully, sending KOD shares up more than 150% in a single session. The results validated the ABC platform and positioned Zenkuda for a three-indication Biologics License Application planned for the fourth quarter of 2026. The broader narrative of a clinical-stage company nearing its first commercial opportunity drove the multi-month re-rating far more than any short-term trading dynamics.

Key Catalysts Ahead

Several milestones could shape KOD's trajectory in the months ahead. The most immediate is the planned fourth-quarter 2026 submission of a Biologics License Application for Zenkuda across wet AMD, diabetic retinopathy, and retinal vein occlusion, followed by KSI-101 PEAK 1 topline data expected in December. Investors will also monitor the tabirafusp-ted ALTO Phase 3 program in diabetic macular edema and further regulatory updates.

Key risks include Kodiak's precommercial status and negative cash flow, which may require additional capital raises, as well as the inherent uncertainty of regulatory review and commercial execution in a competitive ophthalmology market. Macroeconomic conditions and biotech sector sentiment may also influence near-term trading, though clinical and regulatory catalysts are expected to remain the primary drivers. I’m watching this closely as the regulatory timeline unfolds.

Exploring AI Tools in My Research

In my analysis of stocks like this, I often turn to Tickeron’s Trending AI Robots to see how automated strategies are positioning across the market. The page curates top-performing bots from a wide marketplace, helping highlight data-driven approaches that align with current conditions without replacing fundamental review.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: KOD

Contributor

Allana's AvatarAllana|Expert

Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.


Aroon Indicator for KOD shows an upward move is likely

KOD's Aroon Indicator triggered a bullish signal on November 20, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 217 similar instances where the Aroon Indicator showed a similar pattern. In 198 of the 217 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.

Following a +1.14% 3-day Advance, the price is estimated to grow further. Considering data from situations where KOD advanced for three days, in 231 of 273 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.

Bearish Trend Analysis

The 10-day RSI Indicator for KOD moved out of overbought territory on November 16, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 40 similar instances where the indicator moved out of overbought territory. In 36 of the 40 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.

The Momentum Indicator moved below the 0 level on November 20, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on KOD as a result. In 57 of 70 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 81%.

The Moving Average Convergence Divergence Histogram (MACD) for KOD turned negative on November 16, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 39 similar instances when the indicator turned negative. In 32 of the 39 cases the stock turned lower in the days that followed. This puts the odds of success at 82%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where KOD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.

KOD broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. KOD’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: KOD's P/B Ratio (102.150) is slightly higher than the industry average of (3.596). P/E Ratio (-23.699) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (443.347).

The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. KOD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.24B. The market cap for tickers in the group ranges from 58 to 138.67B. VRTX holds the highest valuation in this group at 138.67B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -12%. For the same Industry, the average monthly price growth was -18%, and the average quarterly price growth was -28%. VIVS experienced the highest price growth at 105%, while CUE experienced the biggest fall at -74%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 37%. For the same stocks of the Industry, the average monthly volume growth was 41% and the average quarterly volume growth was -10%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 44
Price Growth Rating: 69
SMR Rating: 93
Profit Risk Rating: 93
Seasonality Score: -3 (-100 ... +100)
AI Patterns 1
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a developer of novel therapies for the treatment of retinal disease

Industry Biotechnology

Industry
Biotechnology
Address
1250 Page Mill Road
Phone
+1 650 281-0850
Employees
124
Web
https://www.kodiak.com
Interact to see
Advertisement
The ADR gapped lower in premarket trading and was at $335.71 in early regular-session trading, -4.65% from Thursday's close of $352.09. The move extends a global AI and chip unwind: investors are cutting crowded semiconductor bets on stretched valuations, rising sector debt, data-center opposition and Nvidia's leadership turmoil, and Nvidia's strong quarter failed to calm sentiment.
Micron shares slid from Thursday's $690.44 close to $635.41, a -7.97% loss, deepening during Friday's regular session after an already soft premarket. The decline was sector-driven, not company-specific: investors kept unwinding AI exposure as Anthropic fell back after its debut, while hawkish Fed comments and doubts about Nvidia's leadership and AI spending returns pressured chip valuations.
Meta Platforms fell from a $596.22 previous close to $583.40, a -2.15% move, with the decline built in premarket trading and held through early Friday action after Thursday's -3.27% drop. The drop was sector-driven, not company-specific: Anthropic slid roughly -6% to -10% premarket on its second trading day, reviving doubts that AI spending will generate returns, and AI-linked megacaps sold off broadly with Nasdaq 100 futures down about -1.5%.
ANT dropped from Thursday's record-debut close of $97.17 to about $88.56 in Friday premarket trading, a -8.86% move ahead of the opening bell, still above its $83 IPO price. The decline came from a broad AI and technology selloff rather than any Anthropic-specific disclosure: Nvidia and AMD traded lower premarket, index futures were sharply down, and renewed doubts over AI spending and valuations drove profit-taking after the +17.07% first-day gain.
IREN dropped -8.33% to $13.21 from Thursday's $14.41 close, with weakness building in premarket and extending through the first hour of regular trading. The decline extends a sector-wide neocloud rout: Anthropic's post-IPO slide and turmoil at Nvidia revived doubts about debt-funded AI data center spending, dragging CoreWeave and Nebius down with it; no IREN-specific news was released.